Seal, Stopping Eczema and Allergy Study
Public ClinicalTrials.gov record NCT03742414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SEAL (Stopping Eczema and ALlergy) Study: Prevent the Allergic March by Enhancing the Skin Barrier
Study identification
- NCT ID
- NCT03742414
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kari Nadeau, MD, PhD
- Other
- Enrollment
- 398 participants
Conditions and interventions
Interventions
- Fluticasone propionate Cream 0.05% Combination Product
- Standard of Care Other
- Tri-lipid skin barrier cream (Epiceram) Combination Product
Combination Product · Other
Eligibility (public fields only)
- Age range
- 1 Week to 12 Weeks
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2021
- Primary completion
- May 30, 2028
- Completion
- Jun 29, 2028
- Last update posted
- Feb 26, 2026
2021 – 2028
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sean N. Parker Center for Allergy & Asthma Research at Stanford University | Palo Alto | California | 94304 | — |
| Division of Pediatric Allergy and Clinical Immunology, National Jewish Health | Denver | Colorado | 80206 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03742414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03742414 live on ClinicalTrials.gov.